Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04468971 · ClinicalTrials.gov registry record · Phase 1
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
A Phase 1 study of Covid19 and ARDS, sponsored by Cellenkos.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT04468971 is a Phase 1 study of Covid19 and ARDS that has completed, run by Cellenkos. The registered enrollment target is 45 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04468971, a Phase 1 study of Covid19 and ARDS, has completed, sponsored by Cellenkos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Interventions
- DRUG Placebo
- BIOLOGICAL CK0802
Study Locations (5)
North Carolina
- University of North Carolina - Chapel Hill
- Wake Forest University - Winston-Salem
Maryland
- Johns Hopkins Hospital - Baltimore
New York
- Columbia University - New York
Texas
- Baylor College of Medicine, St Luke's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04468971
The ClinicalTrials.gov registry entry for NCT04468971 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The listed sponsor is Cellenkos, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04468971 reports 5 study locations spanning 4 distinct geographic areas - top geographies include North Carolina, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT04468971 about?
NCT04468971 is a clinical study titled "REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia". To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
What is the current status of trial NCT04468971?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-09-29. Estimated completion is 2021-10-22.
What conditions does trial NCT04468971 study?
This clinical trial studies the following conditions: Covid19, ARDS.
What interventions are being tested in trial NCT04468971?
The interventions under investigation include: Placebo (DRUG), CK0802 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04468971?
This trial is sponsored by Cellenkos, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04468971 being conducted?
This trial has 5 study locations across Maryland, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MRI of Survivors of COVID-19
ACTIVE NOT RECRUITING · Phase 1
-
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
COMPLETED · Phase 1
-
RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
COMPLETED · Phase 1
-
Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection
COMPLETED · Phase 1
-
COVID-19 Study of Safety and Tolerability of Alvelestat
COMPLETED · Phase 1
-
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.